Access

Streamlined access* for your patients with Access Navigator by Sunovion Answers

Access Navigator by Sunovion Answers is designed to help patients gain streamlined access* to Nebulized BROVANA® (arformoterol tartrate) Inhalation Solution and nebulizer.† 

Access Navigator provides support for patients:

  • Reimbursement support, including insurance verification
  • Delivery of BROVANA and nebulizer,typically within one business day, to the nearest qualified, in-network pharmacy provider*
    • Hospital providers may request an expedited review by calling Access Navigator by Sunovion Answers when faxing the Enrollment Form. Approval is not guaranteed
  • Ongoing telephone support to make sure:
    • Prescribed BROVANA and nebulizer have been received by your patient
    • Your patient knows how to use the nebulizer as instructed by a Healthcare Provider or Pharmacist
    • Your patient knows when it’s time to refill the prescription
  • Toll-free phone number connecting you and your patient with a live support specialist: 1-866-679-1220, Monday-Friday, 8AM – 8PM ET

*Sunovion cannot guarantee availability of medication and/or nebulizer at pharmacies not accessed through Access Navigator by Sunovion Answers.
If applicable for coverage. Completion of the enrollment Form does not guarantee coverage for BROVANA and/or nebulizer.
Fridays excepted. Order and delivery process will be initiated only when a completed form has been received and any insurances have been addressed. 

What HCPs can expect after enrollment in Access Navigator by Sunovion Answers

HCPs will receive an enrollment packet containing:

  • Enrollment instructions for Healthcare Providers: simple steps to guide you and your patient through the enrollment process
  • Patient Brochures: includes instructions for patients and Patient Consent Information
  • Enrollment Forms: Once the Enrollment Form has been completed by you and your patient, simply fax it to 1-800-964-4766 to complete the enrollment process

Download an Enrollment Form for Access Navigator by Sunovion Answers

Enrollment Form for Office-Based HCPs 

Enrollment Form for Hospital-Based HCPs 

 

What patients can expect after enrollment in Access Navigator by Sunovion Answers

Once a completed form has been received, an Access Navigator by Sunovion Answers Site Coordinator will contact your patient to:

  • Review patient healthcare benefits to determine coverage
  • Confirm availability of BROVANA* at the nearest qualified in-network pharmacy
  • Confirm patient receipt of BROVANA and nebulizer* 
  • Make sure patient maintains his/her prescription of BROVANA via prescription-refill reminder calls

*If applicable for coverage. Completion of the enrollment form does not guarantee coverage for BROVANA and/or nebulizer.
Sunovion cannot guarantee availability of medication and/or nebulizer at pharmacies not accessed through Access Navigator by Sunovion Answers.

Important Safety Information & Indication

WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. 

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

For additional information, please see the full Prescribing Information including Boxed Warning, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at www.sunovionprofile.com/brovana.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication
BROVANA® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.